1. UPDATE SURVIVAL OF PHASE 1B CLINICAL TRIAL OF HX008, A NOVEL ANTI-PD-1 MONOCLONAL ANTIBODY, COMBINED WITH GEMCITABINE AND CISPLATIN IN THE FIRST-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER. (October 2021) Authors: Cao, Jun; Hu, Xichun; Wang, Biyun; Zhang, Jian; Wang, Leiping; Tao, Zhonghua; Li, Ting Journal: Breast Issue: Volume 59(2021)supplement 1 Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. WHETHER CHIDAMIDE IMPROVES THE RESPONSE TO CISPLATIN IN FIRST-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER. (October 2021) Authors: Zhang, Jian; Hu, Xichun; Meng, Yanchun; Jin, Juan; Gong, Chengcheng; Miao, Haitao; Tao, Zhonghua; Li, Ting; Cao, Jun; Wang, Leiping; Wang, Biyun; Hu, Xichun Journal: Breast Issue: Volume 59(2021)supplement 1 Page Start: S46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗